5:05 PM
 | 
Feb 15, 2017
 |  BC Innovations  |  Translation in Brief

WinSanTor, with feeling

WinSanTor is inhibiting muscarinic receptors for diabetic neuropathy

The founders of WinSanTor Inc. have discovered that the muscarinic antagonist pirenzepine can stimulate peripheral nerve growth and function and treat a preclinical model of diabetic neuropathy as a topical agent. The company has started a Phase I trial of the compound in the indication, and expects to initiate Phase II this year.

Although pirenzepine, a generic inhibitor of the muscarinic acetylcholine receptor M1 (CHRM1; HM1), is approved in Europe for treating ulcers, it has not been tested for neuropathy. WinSanTor claims it has freedom to operate for topical applications.

“Surprisingly, it was never protected as a topical treatment in humans. No one actually claimed it or even tried to use it as topical. Nobody thought it would actually work topically,” said CEO Stanley Kim.

In fact, the role of cholinergic pathways in regulating growth of peripheral sensory nerves was largely unknown until WinSanTor founders Nigel Calcutt and Paul Fernyhough published...

Read the full 757 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$100 USD
More Info >